ArticleFrontiers in cell and developmental biology2026
Development and validation of an explainable machine learning model for mortality prediction in ICU patients with lung cancer.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung cancer is the leading cause of cancer-related death worldwide, with a particularly high mortality risk among patients admitted to the intensive care unit (ICU). Accurate and timely prediction of in-hospital mortality in this population is critical for clinical decision-making and resource allocation. However, existing severity scoring systems have demonstrated limited discriminative performance in this specific context. This study aimed to develop and validate an interpretable machine learning (ML) model for in-hospital mortality prediction in ICU patients with lung cancer using real-world clinical data from the MIMIC-IV(Medical Information Mart for Intensive Care IV) database. Materials and Methods: Retrospective cohort data were extracted from the MIMIC-IV database. A total of 1,120 ICU admissions of lung cancer patients were included (239 deaths, 21.3%). Candidate variables were systematically screened through univariate analysis, variance inflation factor (VIF) assessment, and bidirectional stepwise logistic regression-all performed exclusively on the training set (70%, n = 785) to prevent data leakage. Eight machine learning algorithms were developed: Logistic Regression (LR), Random Forest (RF), Neural Network (NN), Support Vector Machine (SVM), eXtreme Gradient Boosting (XGBoost), Gradient Boosting Machine (GBM), Adaptive Boosting (AdaBoost), and Decision Tree (DT). Model performance was evaluated on an independent test set (30%, n = 335) using six metrics-Brier score, calibration slope, F1 score, Youden index, area under the receiver operating characteristic curve (AUC), and accuracy (ACC)-with a composite scoring system to rank models. Interpretability was assessed using SHapley Additive exPlanations (SHAP). Clinical utility was evaluated through decision curve analysis (DCA) and comparison with traditional severity scores (Sequential Organ Failure Assessment (SOFA), Simplified Acute Physiology Score II (SAPS II), and Oxford Acute Severity of Illness Score (OASIS)). Subgroup and robustness analyses were also conducted. Results: Five variables were selected as final predictors: SOFA score, SAPS II score, OASIS score, Charlson Comorbidity Index (CCI), and minimum peripheral oxygen saturation (SpO Conclusion: We developed an explainable, LR-based mortality prediction model for ICU lung cancer patients, which outperforms traditional severity scoring systems and provides individual-level clinical interpretability through SHAP values. This model offers a practical and transparent tool to support critical care decision-making in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.